Company Filing History:
2 out of 68 
2 out of 21 
1 out of 14 
Years Active: 2022-2023
Title: Innovations by Nicolas Glaichenhaus
Introduction
Nicolas Glaichenhaus is an accomplished inventor based in Nice, France. He has made significant contributions to the field of medical technology, particularly in the treatment of inflammatory disorders and type 1 diabetes. With a total of two patents to his name, Glaichenhaus is recognized for his innovative approaches to neural signaling.
Latest Patents
Glaichenhaus's latest patents include groundbreaking devices and methods for the stimulation of neural signaling of the apical splenic nerve. This device features a transducer designed for placement on or around the apical splenic nerve, along with a signal generator that produces a signal to stimulate or inhibit neural activity, resulting in a physiological response. The transducer is equipped with at least one electrode, and the signal generator functions as a voltage or current source. The stimulation electrical signal operates at a frequency between 1 Hz and 50 Hz. Additionally, he has developed a method for the modulation of neural signaling of a pancreas-related sympathetic nerve, which has the potential to improve glycaemic control by inhibiting T cell activation or migration to the pancreas, thus offering a novel approach to treating or preventing type 1 diabetes.
Career Highlights
Throughout his career, Glaichenhaus has worked with notable organizations, including Galvani Bioelectronics Limited and the Centre Nationale De La Recherche Scientifique. His work in these institutions has allowed him to advance his research and develop innovative solutions in the medical field.
Collaborations
Glaichenhaus has collaborated with esteemed colleagues such as Arun Sridhar and Philippe Blancou. These partnerships have contributed to the success of his projects and the advancement of his inventions.
Conclusion
Nicolas Glaichenhaus is a prominent inventor whose work in neural signaling has the potential to transform treatments for inflammatory disorders and type 1 diabetes. His innovative patents and collaborations highlight his commitment to advancing medical technology.